Pulmonary Arterial Hypertension Market Insights and Forecast to 2034
ResearchAndMarkets.com has released a market analysis and forecast for Pulmonary Arterial Hypertension (PAH), projecting growth through 2034. The report details market trends, epidemiology, and current treatments across key regions.
The global market for Pulmonary Arterial Hypertension (PAH) is projected to experience consistent growth through 2034, according to a new report by ResearchAndMarkets.com. The study examines market trends, epidemiology, and treatment landscapes in the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan.
The increasing prevalence of PAH is attributed to a rise in cardiovascular diseases and arterial hypertension. Additionally, a growing adult population, which is more susceptible to idiopathic PAH, contributes to the escalating number of cases. This epidemiological shift is expected to drive market expansion over the forecast period.
Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have approved several therapies for PAH, including UPTRAVI (selexipag), REMODULIN (treprostinil), TYVASO (treprostinil), ORENITRAM (treprostinil), and ADEMPAS (riociguat). The market also includes generic versions of established drugs like REVATIO (sildenafil) and TRACLEER (bosentan).
Current therapeutic strategies focus on dilating pulmonary vasculature to decrease resistance and improve right ventricular function, aiming to enhance patient survival, quality of life, and exercise capacity. In 2022, the United States represented the largest PAH market, valued at approximately USD 3.89 billion, with further growth anticipated.